CPHI.AMEXChina Pharma Holdings, INC
10-Q: China Pharma Holdings Reports Q2 2024 Results: Revenue Declines Amidst Market Challenges
Sentiment:
Quarterly Report
China Pharma Holdings reported a decrease in revenue and a net loss for the second quarter of 2024, primarily due to increased competition and the impact of centralized procurement policies in China.
Capital raiseThe company may seek additional debt or equity financing as necessary.There can be no assurance that any additional financing will be available on acceptable terms, if at all.
Worse than expectedThe company's revenue decreased significantly, and the cost of revenue increased substantially, leading to gross losses.The company experienced significant operating and net losses, indicating a deterioration in financial performance compared to the previous year.The company's cash position weakened, and current liabilities exceeded current assets, raising concerns about its financial stability.
Summary
- China Pharma Holdings experienced a 16.4% decrease in revenue for the three months ended June 30, 2024, totaling $0.9 million, compared to $1.1 million in the same period of 2023.
- The company's cost of revenue increased to $1.9 million, or 209.8% of total revenue, for the three months ended June 30, 2024, compared to $1.2 million, or 113.4% of total revenue, in the same period of 2023.
- Gross loss for the three months ended June 30, 2024, was $1.01 million, compared to a gross loss of $0.15 million in the same period of 2023.
- Operating loss for the three months ended June 30, 2024, was $1.4 million, compared to an operating loss of $0.5 million in the same period of 2023.
- Net loss for the three months ended June 30, 2024, was $1.4 million, compared to a net loss of $0.6 million in the same period of 2023.
- For the six months ended June 30, 2024, revenue decreased by 25.0% to $2.3 million, compared to $3.1 million for the same period in 2023.
- The cost of revenue for the six months ended June 30, 2024, was $3.6 million, or 156.9% of total revenue, compared to $3.0 million, or 99.0% of total revenue, in the same period of 2023.
- Gross loss for the six months ended June 30, 2024, was $1.31 million, compared to a gross profit of $0.03 million in the same period of 2023.
- Operating loss for the six months ended June 30, 2024, was $2.31 million, compared to $0.85 million in the same period of 2023.
- Net loss for the six months ended June 30, 2024, was $2.40 million, compared to a net loss of $1.07 million for the same period in 2023.
- The company's cash and cash equivalents were $0.74 million as of June 30, 2024, compared to $1.42 million as of December 31, 2023.
- The company's current liabilities exceeded current assets by $0.7 million as of June 30, 2024.
- The company had an accumulated deficit of $41.7 million as of June 30, 2024.
Sentiment
Score: 2
Explanation: The document paints a very negative picture of the company's current financial health and future prospects. The significant revenue decline, increased costs, substantial losses, and going concern issues indicate a high level of risk and uncertainty. The company's reliance on debt and potential need for further capital raises further contribute to the negative sentiment.
Positives
- The company is exploring strategic alternatives to accelerate the launch of nutrition products.
- Management believes that the company's existing property, plant, and equipment can serve as collateral to support additional bank loans.
- The company has sufficient production capacity for medical masks, surgical masks, KN95 masks, and N95 masks.
- One of the company's flagship products, Candesartan tablets, has passed generic-drug-consistency-evaluation in early August 2023.
Negatives
- The company's revenue decreased significantly due to increased competition and the impact of centralized procurement policies.
- The cost of revenue increased substantially, leading to gross losses.
- The company experienced significant operating and net losses.
- The company's cash and cash equivalents decreased, and current liabilities exceeded current assets.
- The company has a substantial accumulated deficit.
- The company's disclosure controls and procedures were not effective as of June 30, 2024, due to a material weakness in internal control over financial reporting.
- The company's auditors have raised substantial doubt about its ability to continue as a going concern.
Risks
- The company's ability to continue as a going concern is in doubt due to operating losses, negative cash flows, and current liabilities exceeding current assets.
- The company's operations are subject to political, economic, and legal risks in China.
- Fluctuations in foreign currency exchange rates may adversely affect the company's results.
- The company's revenue is denominated in RMB, which is subject to conversion and remittance restrictions.
- The company's products are subject to centralized procurement policies, which can significantly reduce drug prices.
- The company's ability to obtain additional financing is uncertain.
- The company's internal control over financial reporting has a material weakness.
Future Outlook
The company anticipates operating losses to continue for the foreseeable future due to costs related to production, debt service, and selling and administrative expenses. Management plans to enhance the sales model of advance payment, strengthen the collection of accounts receivable, and explore strategic alternatives to accelerate the launch of nutrition products. The company also believes its existing property, plant, and equipment can serve as collateral for additional bank loans.
Management Comments
- Management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable.
- Management believes that the company's existing property, plant and equipment can serve as collateral to support additional bank loans.
- The company is currently exploring strategic alternatives to accelerate the launch of nutrition products.
Industry Context
The company's performance is significantly impacted by the Chinese government's centralized procurement policies, which have led to price reductions for many drugs. The company is also facing challenges related to the consistency evaluation of generic drugs, which is a requirement for participating in centralized procurement. The company is exploring opportunities in the comprehensive healthcare sector, including nutrition products and personal protective equipment, to diversify its revenue streams.
Comparison to Industry Standards
- The company's gross loss margin of 109.8% for the three months ended June 30, 2024, and 56.9% for the six months ended June 30, 2024, is significantly worse than industry standards for pharmaceutical companies, which typically aim for a positive gross profit margin.
- The company's operating and net losses are also concerning, as most established pharmaceutical companies strive for profitability.
- The company's reliance on a few key customers and suppliers, as well as a limited number of products, makes it vulnerable to market fluctuations and supply chain disruptions.
- Compared to larger pharmaceutical companies with diversified product portfolios and established distribution networks, China Pharma is facing significant challenges in the current market environment.
- The company's financial performance is significantly below that of comparable companies such as Hengrui Pharmaceuticals or Sino Biopharmaceutical, which have successfully navigated the challenges of the Chinese pharmaceutical market.
Related Party Transactions
- The company had previously received advances from its Chairperson Li, totaling $1,140,775 as of June 30, 2024.
- Compensation payable to the Chairperson Li is included in Other payables, totaling $1,251,506 as of June 30, 2024.
Stakeholder Impact
- Shareholders are negatively impacted by the company's poor financial performance, declining share price, and the risk of further dilution through potential capital raises.
- Employees may face uncertainty due to the company's financial instability and potential restructuring.
- Customers may be concerned about the company's ability to continue supplying products.
- Suppliers may face increased credit risk due to the company's financial difficulties.
- Creditors face increased risk of non-payment due to the company's financial instability.
Next Steps
- The company plans to enhance the sales model of advance payment.
- The company plans to further strengthen its collection of accounts receivable.
- The company is exploring strategic alternatives to accelerate the launch of nutrition products.
- The company is exploring the possibility of using its existing property, plant and equipment as collateral for additional bank loans.
Key Dates
| Date | Description |
|---|---|
| 2005-05-25 | Onny acquired 100% of the ownership in Helpson. |
| 2005-06-12 | The transaction was approved by the Commercial Bureau of Hainan Province. |
| 2005-06-21 | Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (WFOE) status. |
| 2010-11-12 | The company's Board adopted the 2010 Incentive Plan. |
| 2010-12-22 | The 2010 Incentive Plan was approved by stockholders. |
| 2019-07-08 | The company entered into a loan agreement with its Chairperson Li. |
| 2019-10-17 | The Board of Directors approved the First Amendment to the 2010 Incentive Plan. |
| 2019-12-19 | The First Amendment to the 2010 Incentive Plan was adopted by the stockholders. |
| 2021-11-17 | China Pharma entered into a Securities Purchase Agreement to issue a convertible promissory note. |
| 2021-11-19 | The transaction under the Securities Purchase Agreement was closed. |
| 2021-12-27 | The stockholders adopted the Amendment No.2 to the Plan to increase the number of shares of the Common Stock. |
| 2022-09-30 | The company received a line of credit for RMB 10,000,000 with Bank of China. |
| 2022-11-28 | The company entered into a Technology Transfer Contract with Bonier. |
| 2022-12-21 | The company entered into a new line of credit with Bank of Communications. |
| 2022-12-27 | The stockholders adopted the Amended and Restated Long Term 2010 Incentive Plan. |
| 2023-02-24 | The company received an advance on the line of credit from Bank of Communications. |
| 2023-04-13 | China Pharma entered into an Amendment with the Investor to extend the maturity date of the Convertible Note Payable. |
| 2023-08 | Candesartan tablets passed generic-drug-consistency-evaluation. |
| 2023-09-25 | The company entered into a three-year revolving loan with Bank of China. |
| 2023-12-15 | The company paid in full the line of credit with Bank of Communications. |
| 2023-12-17 | The stockholders approved Amendment No. 1 to the Amended and Restated Long Term 2010 Incentive Plan. |
| 2023-12-20 | The company received a new line of credit from Bank of Communications. |
| 2023-12-31 | End of fiscal year. |
| 2024-01-11 | The Investor delivered its notice of redemption for $150,000 of the Note. |
| 2024-01-16 | The company issued shares of common stock to the Investor. |
| 2024-02-01 | The Investor delivered its notice of redemption for $150,000 of the Note. |
| 2024-02-02 | The company repaid RMB 3,500,000 under the line of credit with Bank of Communications. |
| 2024-02-05 | The company issued shares of common stock to the Investor. |
| 2024-02-16 | The Investor delivered its notice of redemption for $150,000 of the Note. |
| 2024-02-21 | The company issued shares of common stock to the Investor. |
| 2024-02-22 | The company entered into a new agreement with Bank of Communications. |
| 2024-03-06 | The company implemented a 1-for-5 reverse stock split. |
| 2024-04-02 | The Investor delivered its notice of redemption for $150,000 of the Note. |
| 2024-04-03 | The company issued shares of common stock to the Investor. |
| 2024-04-17 | The Investor delivered its notice of redemption for $150,000 of the Note. |
| 2024-04-19 | The company issued shares of common stock to the Investor. |
| 2024-05-20 | The Investor delivered its notice of redemption for $150,000 of the Note. |
| 2024-05-21 | The company issued shares of common stock to the Investor. |
| 2024-05-23 | The company entered into an Amendment No. 2 to the Note. |
| 2024-06-17 | The Investor delivered its notice of redemption for $150,000 of the Note. |
| 2024-06-17 | The company issued shares of common stock to the Investor. |
| 2024-06-30 | End of the quarterly period. |
| 2024-08-12 | Date of share count. |
| 2024-08-14 | Date of report. |
Keywords
pharmaceuticals, China, revenue, net loss, centralized procurement, consistency evaluation, financial results, operating loss, going concern, medical products, healthcare, reverse stock split, convertible note
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.